{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:50:07Z","timestamp":1791820207458,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jdcr.2026.08.045","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:46:45Z","timestamp":1788479205000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Apalutamide-induced drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome overlap successfully treated with cyclosporine and benralizumab: A case report and literature review"],"prefix":"10.1016","volume":"77","author":[{"given":"Alaa","family":"Erras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-8807","authenticated-orcid":false,"given":"Zachary J.","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-7028","authenticated-orcid":false,"given":"Helen H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdcr.2026.08.045_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: a literature review and treatment algorithm","volume":"16","author":"Calle","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"23","key":"10.1016\/j.jdcr.2026.08.045_bib2","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1056\/NEJMra2204547","article-title":"Drug reaction with eosinophilia and systemic symptoms","volume":"391","author":"Kroshinsky","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.045_bib3","article-title":"Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients","volume":"20","author":"Liu","year":"2025","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jdcr.2026.08.045_bib4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2026.08.045_bib5","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.jdcr.2026.08.045_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/DAD.0000000000002742","article-title":"Histopathologic features of drug reaction with eosinophilia and systemic symptoms","volume":"46","author":"Ehsan","year":"2024","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.045_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2026.08.045_bib8","article-title":"Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review","volume":"10","author":"Chen","year":"2023","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.jdcr.2026.08.045_bib9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","volume":"90","author":"Wei","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2026.08.045_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10106","key":"10.1016\/j.jdcr.2026.08.045_bib11","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.045_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.clindermatol.2023.09.005","article-title":"Unraveling the complexities of drug reaction with eosinophilia and systemic symptoms (DRESS): insights into clinical, laboratory, and histopathologic features of a case series from an Italian tertiary center","volume":"41","author":"Schroeder","year":"2023","journal-title":"Clin Dermatol"},{"issue":"8","key":"10.1016\/j.jdcr.2026.08.045_bib13","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1111\/all.15283","article-title":"Targeting interleukin-5 with benralizumab: a novel treatment for drug rash with eosinophilia and systemic symptoms","volume":"77","author":"Maverakis","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.jdcr.2026.08.045_bib14","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1111\/all.16615","article-title":"Deciphering immune endotypes within drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"80","author":"von Wachter","year":"2025","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.jdcr.2026.08.045_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/bjd\/ljae375","article-title":"CCR8\/CCL1 and CXCR3\/CXCL10 axis-mediated memory T-cell activation in patients with recalcitrant drug-induced hypersensitivity","volume":"192","author":"Chiu","year":"2025","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.045_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jdcr.2026.08.045_bib17","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1111\/jdv.18660","article-title":"Drug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome\/toxic epidermal necrolysis related to apalutamide","volume":"37","author":"Hsu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.045_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"},{"issue":"8","key":"10.1016\/j.jdcr.2026.08.045_bib19","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s10147-022-02183-z","article-title":"Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium","volume":"27","author":"Tohi","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jdcr.2026.08.045_bib23","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1111\/1346-8138.17787","article-title":"Apalutamide-Induced Drug-Induced Hypersensitivity Syndrome\/Drug Reaction With Eosinophilia and Systemic Symptoms Involving Reactivation of Human Herpesvirus-6 and Cytomegalovirus: A Case Report","volume":"52","author":"Akai","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdcr.2026.08.045_bib24","doi-asserted-by":"crossref","first-page":"adv40719","DOI":"10.2340\/actadv.v104.40719","volume":"104","author":"Gil-Lianes","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdcr.2026.08.045_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2340\/sju.v59.40198","article-title":"Cutaneous adverse reactions associated to apalumide: two case reports of DRESS syndrome and maculopapular exanthema","volume":"59","author":"Hallamies","year":"2024","journal-title":"Scand J Urol"},{"key":"10.1016\/j.jdcr.2026.08.045_bib26","doi-asserted-by":"crossref","first-page":"1291564","DOI":"10.3389\/fimmu.2023.1291564","article-title":"Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.045_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1159\/000532009","article-title":"Apalutamide-induced toxic epidermal necrolysis in a caucasian patient with metastatic castration-sensitive prostate cancer: a case report and review of the literature","volume":"16","author":"Flynn","year":"2023","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jdcr.2026.08.045_bib27","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.41687","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by apalutamide: a case presentation","author":"Martin","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.jdcr.2026.08.045_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cod.14024","article-title":"The first case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by apalutamide, a novel oral androgen receptor antagonist","volume":"86","author":"Ducharme","year":"2022","journal-title":"Contact Dermatitis"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.045_bib29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cia2.12138","article-title":"A case of toxic epidermal necrolysis associated with apalutamide administration","volume":"3","author":"Sagawa","year":"2020","journal-title":"J Cutan Immunol Allergy"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.045_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of Cyclosporine for the Treatment of DRESS Syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jdcr.2026.08.045_bib22","doi-asserted-by":"crossref","first-page":"100935","DOI":"10.1016\/j.waojou.2024.100935","article-title":"The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids","volume":"17","author":"Wang","year":"2024","journal-title":"World Allergy Organ J"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:27:20Z","timestamp":1791818840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626005424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S2352512626005424"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.045","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apalutamide-induced drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome overlap successfully treated with cyclosporine and benralizumab: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}